Active substance
Zinc sulfate
- US FDA 10
- WHO EML 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZINC SULFATE | EQ 30MG BASE/10ML (EQ 3MG BASE/ML); EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 10MG BASE/10ML (EQ 1MG BASE/ML) | solution · intravenous | AM REGENT | Prescription | 18 Jul 2019 |
| ZINC SULFATE | EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML); EQ 10MG BASE/10ML (EQ 1MG BASE/ML) | solution · intravenous | GLAND | Prescription | 3 May 2022 |
| ZINC SULFATE | EQ 10MG BASE/10ML (EQ 1MG BASE/ML); EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 27 Dec 2022 |
| ZINC SULFATE | EQ 10MG BASE/10ML (EQ 1MG BASE/ML); EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | solution · intravenous | ZYDUS PHARMS | Prescription | 22 Aug 2023 |
| ZINC SULFATE | EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 10MG BASE/10ML (EQ 1MG BASE/ML) | solution · intravenous | APOTEX | Prescription | 10 Jun 2024 |
| ZINC SULFATE | EQ 10MG BASE/10ML (EQ 1MG BASE/ML); EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | solution · intravenous | NIVAGEN | Prescription | 5 Jul 2024 |
| ZINC SULFATE | EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | solution · intravenous | SOMERSET THERAPS LLC | Prescription | 17 Jul 2024 |
| ZINC SULFATE | EQ 10MG BASE/10ML (EQ 1MG BASE/ML); EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | solution · intravenous | ASPIRO | Prescription | 1 May 2025 |
| ZINC SULFATE | EQ 10MG BASE/10ML (EQ 1MG BASE/ML); EQ 25MG BASE/5ML (EQ 5MG BASE/ML); EQ 30MG BASE/10ML (EQ 3MG BASE/ML) | solution · intravenous | STIRA | Prescription | 10 Jun 2025 |
| ZINC SULFATE | EQ 1MG ZINC/ML | injectable · injection | ABRAXIS PHARM | Discontinued | 5 May 1987 |
WHO WHO Model List of Essential Medicines (2025)
- 17.5.2. Medicines for diarrhoea · core
Diarrhoea
Oral > Solid > dispersible tablet: 20 mg (scored)
Safety signals and safety-related labeling changes
- US FDA 30 Jun 2021 TRALEMENT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations
Combinations containing Zinc sulfate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.